Yuzhuo Wang

List of Publications by Year in Descending Order

201 papers	11,318 citations	59 h-index	100 g-index
226 ext. papers	13,497 ext. citations	7.6 avg, IF	5.92 L-index

#	Paper	IF	Citations
201	Patient-derived xenograft models of neuroendocrine prostate cancer. *Cancer Letters*, **2022**, 525, 160-169	9.9	1
200	Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 105	12.8	6
199	The long and short non-coding RNAs modulating EZH2 signaling in cancer.. *Journal of Hematology and Oncology*, **2022**, 15, 18	22.4	12
198	Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine: Stimuli-responsive carriers, co-delivery and suppressing resistance.. *Expert Opinion on Drug Delivery*, **2022**,	8	5
197	Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.. *Nature*, **2021**,	50.4	10
196	: an insight into lncRNA genetic evolution. *Epigenomics*, **2021**, 13, 1831-1843	4.4	3
195	A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. *Nature Communications*, **2021**, 12, 1521	17.4	11
194	Androgen receptor (AR) antagonism triggers acute succinate-mediated adaptive responses to reactivate AR signaling. *EMBO Molecular Medicine*, **2021**, 13, e13427	12	1
193	The evolutionarily conserved long non-coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms. *Molecular Oncology*, **2021**, 15, 1921-1941	7.9	9
192	Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13. *Cancer Science*, **2021**, 112, 2781-2791	6.9	2
191	Long non-coding RNAs in the doxorubicin resistance of cancer cells. *Cancer Letters*, **2021**, 508, 104-114	9.9	42
190	Molecular events in neuroendocrine prostate cancer development. *Nature Reviews Urology*, **2021**, 18, 581-596	5.5	11
189	GRB10 sustains AR activity by interacting with PP2A in prostate cancer cells. *International Journal of Cancer*, **2021**, 148, 469-480	7.5	1
188	ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 775-785	6.2	
187	SPOP mutation induces DNA methylation via stabilizing GLP/G9a. *Nature Communications*, **2021**, 12, 5716	17.4	2
186	SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition. *Nature Communications*, **2021**, 12, 5779	17.4	2
185	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.. *Nature Communications*, **2021**, 12, 7349	17.4	10

184	Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. *Neoplasia*, **2020**, 22, 253-262	6.4	9
183	Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma. *Cancers*, **2020**, 12,	6.6	8
182	Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development. *Cells*, **2020**, 9,	7.9	8
181	LncRNA promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism. *Epigenomics*, **2020**, 12, 1123-1138	4.4	7
180	A synopsis of prostate organoid methodologies, applications, and limitations. *Prostate*, **2020**, 80, 518-526	4.2	9
179	PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target. *Gene*, **2020**, 744, 144608	3.8	11
178	Long Non-coding RNAs and Cancer Cells Drug Resistance: An Unexpected Connection. *RNA Technologies*, **2020**, 167-198	0.2	1
177	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. *European Urology*, **2020**, 78, 834-844	10.2	23
176	Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for F-FDG Imaging of PSMA-Suppressed Tumors. *Journal of Nuclear Medicine*, **2020**, 61, 904-910	8.9	26
175	Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	40
174	EZH2 inhibition: a promising strategy to prevent cancer immune editing. *Epigenomics*, **2020**, 12, 1457-1476	4.4	12
173	ETS transcription factors as emerging drug targets in cancer. *Medicinal Research Reviews*, **2020**, 40, 413-430	13.4	24
172	The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management. *European Urology*, **2019**, 76, 546-559	10.2	56
171	Potential Therapies for Infectious Diseases Based on Targeting Immune Evasion Mechanisms That Pathogens Have in Common With Cancer Cells. *Frontiers in Cellular and Infection Microbiology*, **2019**, 9, 25	5.9	6
170	ONECUT2 is a driver of neuroendocrine prostate cancer. *Nature Communications*, **2019**, 10, 278	17.4	72
169	An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. *Molecular Metabolism*, **2019**, 25, 119-130	8.8	28
168	Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. *Science Translational Medicine*, **2019**, 11,	17.5	56
167	RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. *European Urology*, **2019**, 76, 157-166	10.2	12

166	The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program. *Molecular Oncology*, **2019**, 13, 1121-1136	7.9	21
165	Exonuclease 1 expression is associated with clinical progression, metastasis, and survival prognosis of prostate cancer. *Journal of Cellular Biochemistry*, **2019**, 120, 11383	4.7	9
164	T-type calcium channels drive the proliferation of androgen-receptor negative prostate cancer cells. *Prostate*, **2019**, 79, 1580-1586	4.2	5
163	The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. *EMBO Molecular Medicine*, **2019**, 11, e10659	12	37
162	Activity of NEO2734, a novel dual inhibitor of both BET and CBP-P300, in SPOP-mutated prostate cancer.. *Journal of Clinical Oncology*, **2019**, 37, 62-62	2.2	3
161	BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. *Genome Medicine*, **2019**, 11, 8	14.4	52
160	Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis. *EMBO Reports*, **2019**, 20, e48375	6.5	44
159	Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines. *International Journal of Endocrine Oncology*, **2019**, 6, IJE20	0.3	3
158	SRRM4 gene expression correlates with neuroendocrine prostate cancer. *Prostate*, **2019**, 79, 96-104	4.2	16
157	Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer. *Clinical Cancer Research*, **2019**, 25, 595-608	12.9	29
156	Heterochromatin Protein 1Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. *Cancer Research*, **2018**, 78, 2691-2704	10.1	31
155	Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. *International Journal of Cancer*, **2018**, 143, 419-429	7.5	5
154	Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer. *British Journal of Cancer*, **2018**, 118, 802-812	8.7	9
153	Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy. *Angewandte Chemie - International Edition*, **2018**, 57, 1510-1513	16.4	117
152	Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy. *Angewandte Chemie*, **2018**, 130, 1526-1529	3.6	20
151	Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. *European Urology*, **2018**, 73, 949-960	10.2	9
150	Patient-derived xenografts: A platform for accelerating translational research in prostate cancer. *Molecular and Cellular Endocrinology*, **2018**, 462, 17-24	4.4	14
149	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. *European Urology*, **2018**, 73, 524-532	10.2	35

148	Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts. *Frontiers in Genetics*, **2018**, 9, 232	4.5	7
147	Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. *Prostate*, **2018**, 78, 1262-1282	4.2	44
146	Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer. *Cancer Medicine*, **2018**, 7, 3385	4.8	30
145	Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. *Endocrine-Related Cancer*, **2018**, 26, 131-146	5.7	44
144	TMEM45B is a novel predictive biomarker for prostate cancer progression and metastasis. *Neoplasma*, **2018**, 65, 815-821	3.3	3
143	Is HOTAIR really involved in neuroendocrine prostate cancer differentiation?. *Epigenomics*, **2018**, 10, 1259-1261	4.4	4
142	Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. *Molecular Cancer Therapeutics*, **2018**, 17, 2746-2755	6.1	34
141	Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. *Journal of Cancer*, **2018**, 9, 3196-3207	4.5	25
140	The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. *GigaScience*, **2018**, 7,	7.6	35
139	Prevention of Prostate Tumor Development by Stimulation of Antitumor Immunity Using a Standardized Herbal Extract (Deep Immune) in TRAMP Mice. *Evidence-based Complementary and Alternative Medicine*, **2018**, 2018, 9707543	2.3	3
138	SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. *European Urology*, **2017**, 71, 68-78	10.2	105
137	Prospectives. *Molecular and Translational Medicine*, **2017**, 193-200	0.4	
136	Patient-Derived Tumor Xenografts: Historical Background. *Molecular and Translational Medicine*, **2017**, 1-9	0.4	
135	Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. *Nature Medicine*, **2017**, 23, 1055-1062	50.5	149
134	miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer. *Scientific Reports*, **2017**, 7, 4079	4.9	25
133	A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. *Journal of Physical Education and Sports Management*, **2017**, 3,	2.8	15
132	Hormonal Carcinogenesis: The Role of Estrogens **2017**, 307-322		
131	The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. *Cancer Discovery*, **2017**, 7, 54-71	24.4	173

130	Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer. *Clinical Cancer Research*, **2017**, 23, 1542-1551	12.9	17
129	Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation. *PLoS ONE*, **2017**, 12, e0182818	3.7	13
128	Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner. *Oncotarget*, **2017**, 8, 9617-9633	3.3	13
127	Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. *Oncotarget*, **2017**, 8, 25928-25941	3.3	12
126	Biological and Clinical Evidence for Metabolic Dormancy in Solid Tumors Post Therapy. *Cancer Drug Discovery and Development*, **2017**, 17-29	0.3	1
125	Immuno-oncology of Dormant Tumours. *Cancer Drug Discovery and Development*, **2017**, 51-60	0.3	1
124	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. *Blood*, **2016**, 127, 2203-13	2.2	51
123	Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. *Clinical Epigenetics*, **2016**, 8, 16	7.7	44
122	Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. *Molecular Oncology*, **2016**, 10, 693-703	7.9	33
121	The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer. *Clinical Cancer Research*, **2016**, 22, 2721-33	12.9	57
120	Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. *Genes and Cancer* , **2016**, 7, 340-354	2.9	18
119	An Aqueous Extract of Marine Microalgae Exhibits Antimetastatic Activity through Preferential Killing of Suspended Cancer Cells and Anticolony Forming Activity. *Evidence-based Complementary and Alternative Medicine*, **2016**, 2016, 9730654	2.3	11
118	Elevated XPO6 expression as a potential prognostic biomarker for prostate cancer recurrence. *Frontiers in Bioscience - Scholar*, **2016**, 8, 44-55	2.4	9
117	Elevated expression of the centromere protein-A(CENP-A)-encoding gene as a prognostic and predictive biomarker in human cancers. *International Journal of Cancer*, **2016**, 139, 899-907	7.5	60
116	Subrenal capsule grafting technology in human cancer modeling and translational cancer research. *Differentiation*, **2016**, 91, 15-9	3.5	21
115	The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer. *Epigenomics*, **2016**, 8, 721-31	4.4	80
114	Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?. *Asian Journal of Urology*, **2016**, 3, 195-202	2.7	10
113	Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth. *Clinical Cancer Research*, **2015**, 21, 1675-87	12.9	90

112	The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. *Molecular Cancer*, **2015**, 14, 46	42.1	59
111	The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. *International Journal of Cancer*, **2015**, 136, E27-38	7.5	61
110	Polycomb-mediated silencing in neuroendocrine prostate cancer. *Clinical Epigenetics*, **2015**, 7, 40	7.7	70
109	YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. *Journal of Cell Biology*, **2015**, 208, 913-29	7.3	154
108	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. *Clinical Cancer Research*, **2015**, 21, 2315-24	12.9	334
107	Translational Activation of HIF1 by YB-1 Promotes Sarcoma Metastasis. *Cancer Cell*, **2015**, 27, 682-97	24.3	167
106	The epigenetic/noncoding origin of tumor dormancy. *Trends in Molecular Medicine*, **2015**, 21, 206-11	11.5	39
105	Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. *Epigenomics*, **2015**, 7, 757-65	4.4	18
104	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. *Cell Reports*, **2015**, 12, 922-36	10.6	155
103	Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. *Nature*, **2015**, 518, 422-6	50.4	451
102	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. *BMC Cancer*, **2015**, 15, 874	4.8	8
101	miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. *Oncotarget*, **2015**, 6, 6092-104	3.3	73
100	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. *JAMA Oncology*, **2015**, 1, 466-74	13.4	207
99	Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. *Oncotarget*, **2015**, 6, 1806-20	3.3	33
98	Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. *Oncotarget*, **2015**, 6, 21522-32	3.3	30
97	The Non-Coding Transcriptome as a Dynamic Regulator of Prostate Cancer Metastasis. *FASEB Journal*, **2015**, 29, 221.3	0.9	
96	Transmembrane and coiled-coil domain family 1 is a novel protein of the endoplasmic reticulum. *PLoS ONE*, **2014**, 9, e85206	3.7	10
95	The role of mRNA splicing in prostate cancer. *Asian Journal of Andrology*, **2014**, 16, 515-21	2.8	18

94	High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. *Cancer Research*, **2014**, 74, 1272-83	10.1	250
93	INPP4B suppresses prostate cancer cell invasion. *Cell Communication and Signaling*, **2014**, 12, 61	7.5	28
92	Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. *Genome Biology*, **2014**, 15, 426	18.3	57
91	Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer. *Molecular Endocrinology*, **2014**, 28, 1629-39		31
90	Lessons from patient-derived xenografts for better in vitro modeling of human cancer. *Advanced Drug Delivery Reviews*, **2014**, 79-80, 222-37	18.5	126
89	REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. *Nucleic Acids Research*, **2014**, 42, 999-1015	20.1	93
88	Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. *Molecular Oncology*, **2014**, 8, 311-22	7.9	21
87	The non-coding transcriptome as a dynamic regulator of cancer metastasis. *Cancer and Metastasis Reviews*, **2014**, 33, 1-16	9.6	74
86	Systematic identification and characterization of RNA editing in prostate tumors. *PLoS ONE*, **2014**, 9, e101431	3.7	14
85	A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines. *PLoS ONE*, **2014**, 9, e103050	3.7	6
84	GATA2 as a potential metastasis-driving gene in prostate cancer. *Oncotarget*, **2014**, 5, 451-61	3.3	49
83	Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. *Oncotarget*, **2014**, 5, 764-74	3.3	184
82	The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. *Oncotarget*, **2014**, 5, 6896-908	3.3	24
81	Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification. *Asian Journal of Andrology*, **2014**, 16, 545-8	2.8	6
80	Next generation patient-derived prostate cancer xenograft models. *Asian Journal of Andrology*, **2014**, 16, 407-12	2.8	22
79	Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite?. *Journal of Pathology*, **2013**, 230, 350-5	9.4	178
78	Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex. *Prostate*, **2013**, 73, 455-66	4.2	36
77	Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. *Journal of Experimental and Clinical Cancer Research*, **2013**, 32, 77	12.8	37

76	Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance. *Journal of Thoracic Oncology*, **2013**, 8, 161-70	8.9	30
75	Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. *International Journal of Molecular Sciences*, **2013**, 14, 7757-70	6.3	98
74	Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage. *Carcinogenesis*, **2013**, 34, 257-67	4.6	27
73	Lessons from in-vivo models of castration-resistant prostate cancer. *Current Opinion in Urology*, **2013**, 23, 214-9	2.8	8
72	Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 2887-96	5.6	62
71	The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. *Asian Journal of Andrology*, **2013**, 15, 301-8	2.8	33
70	Deletion of leucine zipper tumor suppressor 2 (Lzts2) increases susceptibility to tumor development. *Journal of Biological Chemistry*, **2013**, 288, 3727-38	5.4	17
69	ERBB4 confers metastatic capacity in Ewing sarcoma. *EMBO Molecular Medicine*, **2013**, 5, 1087-102	12	59
68	Genistein versus ICI 182, 780: an ally or enemy in metastatic progression of prostate cancer. *Prostate*, **2013**, 73, 1747-60	4.2	13
67	BIRC6 protein, an inhibitor of apoptosis: role in survival of human prostate cancer cells. *PLoS ONE*, **2013**, 8, e55837	3.7	22
66	Chromoplexy: a new paradigm in genome remodeling and evolution. *Asian Journal of Andrology*, **2013**, 15, 711-2	2.8	5
65	Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models. *Carcinogenesis*, **2012**, 33, 2558-67	4.6	46
64	Epithelial immune cell-like transition (EIT): a proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers. *Differentiation*, **2012**, 83, 293-8	3.5	19
63	Poly-gene fusion transcripts and chromothripsis in prostate cancer. *Genes Chromosomes and Cancer*, **2012**, 51, 1144-53	5	39
62	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. *Journal of Pathology*, **2012**, 227, 286-97	9.4	142
61	Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis. *Carcinogenesis*, **2012**, 33, 1391-8	4.6	59
60	Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. *Molecular Cancer Therapeutics*, **2012**, 11, 775-83	6.1	30
59	Drug sensitivity testing for personalized lung cancer therapy. *Journal of Thoracic Disease*, **2012**, 4, 17-8	2.6	25

58	The immunoregulatory mechanisms of carcinoma for its survival and development. *Journal of Experimental and Clinical Cancer Research*, **2011**, 30, 12	12.8	41
57	CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis. *American Journal of Pathology*, **2011**, 179, 2100-7	5.8	28
56	Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. *Blood*, **2011**, 118, 3350-8	2.2	81
55	Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. *Cancer Discovery*, **2011**, 1, 487-95	24.4	550
54	Genistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancer. *PLoS ONE*, **2011**, 6, e20034	3.7	52
53	MicroRNAs associated with metastatic prostate cancer. *PLoS ONE*, **2011**, 6, e24950	3.7	163
52	Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer. *PLoS ONE*, **2011**, 6, e28670	3.7	41
51	Use of irinotecan for treatment of small cell carcinoma of the prostate. *Prostate*, **2011**, 71, 675-81	4.2	21
50	Collagen triple helix repeat containing 1 promotes melanoma cell adhesion and survival. *Journal of Cutaneous Medicine and Surgery*, **2011**, 15, 103-10	1.6	26
49	Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. *Clinical Cancer Research*, **2011**, 17, 783-91	12.9	64
48	Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. *PLoS ONE*, **2011**, 6, e21121	3.7	63
47	Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. *Oncogene*, **2010**, 29, 3593-604	9.2	103
46	Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. *Clinical Cancer Research*, **2010**, 16, 1442-51	12.9	150
45	Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor. *Sarcoma*, **2010**, 2010, 174528	3.1	26
44	Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 3123-8	11.5	153
43	Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer. *Cancer Letters*, **2010**, 292, 176-85	9.9	20
42	Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. *Cancer Cell*, **2010**, 17, 535-46	24.3	377
41	Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor. *Prostate*, **2010**, 70, 1636-44	4.2	30

40	Response to Savaskan NE et al. The x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases: Yet another cytotoxic anticancer approach? *Journal of Cellular Physiology*, **2009**, 220, 533-534	7	2
39	The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. *Cancer Chemotherapy and Pharmacology*, **2009**, 64, 463-72	3.5	86
38	Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. *Cancer Research*, **2009**, 69, 8386-94	10.1	161
37	A novel protein isoform of the multicopy human NAIP gene derives from intragenic Alu SINE promoters. *PLoS ONE*, **2009**, 4, e5761	3.7	43
36	The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. *British Journal of Cancer*, **2008**, 99, 464-72	8.7	132
35	Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. *Gynecologic Oncology*, **2008**, 110, 256-64	4.9	54
34	Decitabine-induced demethylation of 5' CpG island in GADD45A leads to apoptosis in osteosarcoma cells. *Neoplasia*, **2008**, 10, 471-80	6.4	45
33	Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. *FASEB Journal*, **2008**, 22, 1512-20	0.9	174
32	ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. *Cancer Research*, **2008**, 68, 4352-9	10.1	73
31	The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. *Journal of Cellular Physiology*, **2008**, 215, 593-602	7	293
30	Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: identification of apoptotic genes as targets for demethylation. *Cancer Cell International*, **2007**, 7, 14	6.4	40
29	Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. *Prostate*, **2007**, 67, 162-71	4.2	85
28	Bisphenol A induces permanent squamous change in mouse prostatic epithelium. *Differentiation*, **2007**, 75, 745-56	3.5	33
27	Steroid hormones and carcinogenesis of the prostate: the role of estrogens. *Differentiation*, **2007**, 75, 871-82	3.5	52
26	The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. *Cancer Research*, **2007**, 67, 967-75	10.1	150
25	Molecular analysis and characterization of PrEC, commercially available prostate epithelial cells. *In Vitro Cellular and Developmental Biology - Animal*, **2006**, 42, 33-9	2.6	13
24	Steroid hormones stimulate human prostate cancer progression and metastasis. *International Journal of Cancer*, **2006**, 118, 2123-31	7.5	79
23	MOLECULAR ANALYSIS AND CHARACTERIZATION OF PrEC, COMMERCIALLY AVAILABLE PROSTATE EPITHELIAL CELLS. *In Vitro Cellular and Developmental Biology - Animal*, **2006**, 42, 33	2.6	1

22	Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. *Clinical Cancer Research*, **2006**, 12, 4043-54	12.9	94
21	Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. *Current Cancer Drug Targets*, **2006**, 6, 455-89	2.8	28
20	An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. *Laboratory Investigation*, **2005**, 85, 1392-404	5.9	95
19	Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. *Gynecologic Oncology*, **2005**, 96, 48-55	4.9	80
18	Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. *Prostate*, **2005**, 64, 149-59	4.2	147
17	The ontogeny of the urogenital system of the spotted hyena (Crocuta crocuta Erxleben). *Biology of Reproduction*, **2005**, 73, 554-64	3.9	26
16	Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. *Journal of Steroid Biochemistry and Molecular Biology*, **2004**, 92, 221-36	5.1	242
15	Rescue and isolation of Rb-deficient prostate epithelium by tissue recombination. *Methods in Molecular Biology*, **2003**, 218, 17-33	1.4	3
14	hZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci. *EMBO Journal*, **2003**, 22, 6101-14	13	85
13	Urogenital system of the spotted hyena (Crocuta crocuta Erxleben): a functional histological study. *Journal of Morphology*, **2003**, 256, 205-18	1.6	23
12	Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. *Prostate*, **2003**, 54, 212-9	4.2	44
11	Rescue of embryonic epithelium reveals that the homozygous deletion of the retinoblastoma gene confers growth factor independence and immortality but does not influence epithelial differentiation or tissue morphogenesis. *Journal of Biological Chemistry*, **2002**, 277, 44475-84	5.4	28
10	Estrogenic effects on prostatic differentiation and carcinogenesis. *Reproduction, Fertility and Development*, **2001**, 13, 285-96	1.8	64
9	Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. *Cell Death and Differentiation*, **2001**, 8, 192-200	12.7	150
8	Cell differentiation lineage in the prostate. *Differentiation*, **2001**, 68, 270-9	3.5	222
7	Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium. *Developmental Biology*, **2001**, 229, 432-42	3.1	144
6	The BMP family member Gdf7 is required for seminal vesicle growth, branching morphogenesis, and cytodifferentiation. *Developmental Biology*, **2001**, 234, 138-50	3.1	49
5	Growth factors and epithelial-stromal interactions in prostate cancer development. *International Review of Cytology*, **2000**, 199, 65-116		70

4	Changes in serum and tissue zinc levels in sex hormone-induced prostatic carcinogenesis in the noble rat. *Tumor Biology*, **2000**, 21, 328-36	2.9	8
3	Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. *Prostate*, **1998**, 35, 165-77	4.2	90
2	Oncogenes and tumor suppressor genes in prostate cancer: a review. *Urologic Oncology: Seminars and Original Investigations*, **1997**, 3, 41-6	2.8	14
1	The influence of mesenchyme of neonatal seminal vesicle and embryonic urogenital sinus on the morphologic and functional cytodifferentiation of dunning prostatic adenocarcinoma: Roles of growth factors and proto-oncogenes. *Urologic Oncology: Seminars and Original Investigations*, **1997**, 3, 85-93	2.8	9